• Amy L Olson, Alex H Gifford, Naohiko Inase, Evans R Fernández Pérez, and Takafumi Suda.
• Interstitial Lung Disease Program, Autoimmune Lung Center, Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, USA.
• Eur Respir Rev. 2018 Dec 31; 27 (150).

AbstractThe availability of epidemiological data relating to interstitial lung diseases (ILDs) has increased over recent years, but information on the prevalence and incidence of ILDs of different aetiologies remains limited. Despite global distribution, the proportion of patients who develop a progressive phenotype across different ILDs is not well known. Disease behaviour is well documented in idiopathic pulmonary fibrosis but idiosyncratic in other ILDs that may present a progressive fibrosing phenotype. Possible reasons may include the heterogeneous nature of the aetiology, the complexity of diagnosis (and subsequent documentation of cases) and the methods employed to retrospectively analyse patient databases. This review presents a broad overview of the epidemiological data available for ILDs that may present a progressive-fibrosing phenotype, collectively and stratified according to clinical classification. We also note where further data are needed in comparison to the well-studied IPF indication.Copyright ©ERS 2018.

28 keywords...

hide…